Pharmacokinetic parameters of bictegravir in breastmilk of healthy, lactating volunteers without HIV after a single dose of 50 mg (co‐formulated with emtricitabine 200 mg and tenofovir alafenamide 25 mg)

Documents similaires

• Physiologically based pharmacokinetic model combined with a clinical lactation study to determine doravirine concentrations in human breastmilk
  par: Lena van der Wekken‐Pas, et autres
  Publié: (2025)
• Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV
  Publié: (2024)
• Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats
  Publié: (2024)
• No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis
  par: Nimish Patel, et autres
  Publié: (2024)
• Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers
  par: Lisanne K. A. Neijenhuis, et autres
  Publié: (2026)